Search:
 
This image is of a spacer graphic
NHF Face Book NHF Twitter
+ Login to my NHF
+ NHF Membership
+ Donate to NHF
+ Chapter Center
+ Hechos y Respuestas Rápidas
+ Ethics Advisory Committee
This image is of a spacer graphic
-News
 NHF In The News
 NHF eNotes
 Medical Advisories
 Advocacy and Legislative Updates
 Medical News
 Blood Safety News
 NHF and Community News
-Industry News
 Travel Advisory

 

 

 
Grifols Tightens Distribution Channels for Its Products
 

Grifols S.A. released a “Customer Alert” to apprise the community of steps the
pharmaceutical company has implemented to protect the integrity and security of its drug
products. It is cracking down on unauthorized channels of distribution that might
compromise the safety of Grifols’ drugs.

These steps include: placing restrictions on the acquisition and resale of Grifols products;
making public an authorized distributor list; mailing out “on-notice” letters to
unauthorized distributors; and improving distributor reporting and inspection
requirements.

Grifols manufactures several products used to treat patients with bleeding disorders.
Alphanate® is a plasma-derived factor concentrate for preventing and controlling
bleeding in patients with hemophilia A or acquired Factor VIII deficiency. AlphaNine®
is a plasma-derived factor concentrate for preventing and controlling bleeding in patients
with hemophilia B. Profilnine® is a plasma-derived factor concentrate for patients with
either factors II, VII or X deficiency.

Source: Grifols Customer Alert, April 2006